This story was originally published by CalMatters. Sign up for their newsletters. Guest Commentary written by Julie Gill Shuffield Julie Gill Shuffield is executive director of Patients Come ...
New York City has long stood at the center of New York’s fight to expand healthcare access. Our boroughs, especially in ...
Hospital groups and 340B advocates counter that the discounts are a financial lifeline that helps fund community health ...
AbbVie Inc. (NYSE:ABBV) is included among the 15 Best Cheap Dividend Stocks to Buy. On April 8, Cantor Fitzgerald lowered its ...
On April 8, Cantor Fitzgerald lowered its price recommendation on AbbVie Inc. (NYSE:ABBV) to $240 from $250. It kept an ...
Pharmacy benefit managers (PBMs) are now facing the same transparency and accountability requirements that employers and ...
The U.S. Court of Appeals for the 5th Circuit today affirmed rulings by a Mississippi district court that rejected requests by Novartis and PhRMA to enjoin enforcement of the state’s law protecting ...
Taking GLP-1s once meant injecting a shot with a monthly price tag of $1,000. Today, patients interested in the wildly ...
While federal and state legislators contemplate the next wave of PBM and drug pricing reform, legislatures in Virginia and ...
Plenful, the leading AI workflow automation platform for pharmacy teams, today announced the launch of its MFP Intelligence ...
AbbVie is spearheading a new battle in pharma’s long-running fight to reform the federal government’s 340B drug discount ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results